Eisai’s Embolic Beads For Hepatocellular Carcinoma Approved In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai received manufacturing and marketing approval in Japan for its DC Bead used in transcatheter arterial embolization in patients with hepatocellular carcinoma, the company announced April 17.
You may also be interested in...
COVID-19: New Emergency Guidance From AAMI Targets Remote-Controlled Devices
Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.
Radical Shake-Up In Store For Entire EU Pharma Legislation
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Need a specific report? 1000+ reports available
Buy Reports